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ACE I/D polymorphism is associated with mortality in a cohort
study of patients starting with dialysis.
Background. In dialysis patients, only a few follow-up studies
have addressed the relationship between the insertion/deletion
(I/D) polymorphism in the angiotensin-converting enzyme
(ACE) gene and mortality, but the available data are contra-
dictory.
Methods. A cohort of 453 consecutive patients starting dialy-
sis between January 1999 and January 2002 and participating in
a Dutch multicenter prospective study was examined. Patients
who died within 3 months after the start of dialysis were ex-
cluded. Patients were followed until date of death or censoring
in November 2003.
Results. The ACE II, ID, and DD genotype frequencies were
24.3% (N = 110), 50.1% (N = 227), and 25.6% (N = 116). Be-
sides a slightly higher number of Caucasians in the DD group,
all other patient characteristics of the 3 ACE groups were simi-
lar at the start of dialysis. After adjustment for age, comorbidity,
and ethnic background, patients with the ID and DD genotype
showed an increased hazard ratio (HR) for all-cause mortality
of 1.55 (95% CI 1.00–2.42) and 2.30 (95% CI 1.41–3.75), com-
pared to patients with the II genotype. Slightly lower HRs were
found for cardiovascular mortality. All groups of primary kid-
ney disease showed a 2- to 3-fold increased adjusted HR for
DD.
Conclusion. The DD genotype identifies dialysis patients at
an increased risk for mortality.
Cardiovascular disease (CVD) is the major cause of
morbidity and mortality in dialysis patients [1, 2]. In the
United States about 50% of deaths among dialysis pa-
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tients is caused by CVD [2], whereas in Europe cardiac
death accounts for 36% of deaths [1]. Compared to the
general population, cardiovascular mortality is 10 to 20
times higher in dialysis patients [3].
Angiotensin-converting enzyme (ACE) is a key
enzyme in the renin-angiotensin-aldosterone system
(RAAS). The ACE gene contains a diallelic polymor-
phism in intron 16. This insertion/deletion (I/D) poly-
morphism accounts for about 50% of the variation in
plasma and tissue ACE levels [4–6]. Compared to subjects
with the II genotype, DD homozygotes have the highest
plasma and tissue ACE levels, whereas ID heterozygotes
have intermediate levels [4–6].
In 1992, Cambien et al [7] found that the DD geno-
type is associated with myocardial infarction. Since then
numerous studies have investigated the possible role of
I/D polymorphism as cardiovascular risk factor in vari-
ous study populations, but consensus of opinion was not
reached. Three meta-analyses showed a positive associ-
ation between the DD genotype and CVD [8–10]. How-
ever, these findings were contradicted by a meta-analysis
of Agerholm-Larsen et al [11], who performed sensitivity
analyses on small and large studies separately.
In patients with renal failure, most studies have focused
on the impact of I/D polymorphism on the progression
of renal disease. A review published in 1999 [12], but
also more recent prospective follow-up studies [13, 14],
showed that the DD genotype is associated with increased
progression of renal failure towards end-stage renal dis-
ease (ESRD). The effect of I/D polymorphism on the
occurrence of CVD in renal disease is less pronounced.
A positive association of the DD genotype with left ven-
tricular hypertrophy [15], fatal and nonfatal CVD [16],
and cerebrovascular disease [17] has been reported in
ESRD patients, whereas others did not find such an effect
[18–20].
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In dialysis patients, there are only a few follow-up stud-
ies available that have investigated the relationship be-
tween I/D polymorphism and mortality [16, 18, 20–22].
The results of these studies were contradictory, probably
because most of these study populations consisted of pa-
tients who had been on dialysis treatment for a long time
before the study was started. Furthermore, the 2 follow-
up studies reporting a positive association between DD
genotype and mortality were performed in diabetic dial-
ysis patients [20] or in hemodialysis (HD) patients only
[22]. These studies were both conducted in Japan, a coun-
try with a rather low D-allele frequency (about 38%) [20,
22] compared to Caucasian populations [23].
At the moment it is unclear whether the DD genotype
is a risk factor for mortality in dialysis patients. There-
fore, we have investigated the relationship between I/D
polymorphism and all-cause and cardiovascular mortal-
ity in Dutch dialysis patients who were followed from
the start of dialysis onwards (i.e., incident patients). Due
to the large number of dialysis patients in our follow-up
study, we were also able to study the ACE-related mortal-
ity risk in patients with various primary kidney diseases
either treated with HD or peritoneal dialysis (PD).
METHODS
Netherlands Cooperative Study on the Adequacy of
Dialysis (NECOSAD) patients
NECOSAD is a multicenter, prospective follow-up
study in which incident ESRD patients are included con-
secutively at the time of initiation of dialysis. Eligibility
criteria were: 18 years and older and no previous renal
replacement therapy. All patients gave informed consent
before inclusion. All local medical ethics committees gave
their approval to the study.
For the current analyses, data were used from patients
who were included between January 1999 and January
2002 in dialysis centers that gave permission for DNA
analyses (19 out of 38 participating centers). Patients
who died within 3 months after the start of dialysis were
excluded from the current analyses because other than
dialysis-related clinical factors might have contributed to
their rapid decease. Patients were followed until date of
death or date of censoring. Surviving patients were con-
sidered to have their survival times censored at the date of
leaving the study as a result of a renal transplant, a trans-
fer to a nonparticipating dialysis center, withdrawal from
the study, or at the end of the follow-up period (Novem-
ber 2003).
Comparison group
Data of 472 Dutch healthy adult control subjects from
the Leiden Trombophilia Study (LETS) were used for
comparison of ACE genotype and allele distribution with
the NECOSAD patients. The LETS is a large population-
based case-control study on risk factors for venous throm-
bosis [24, 25]. Control subjects were friends or partners of
patients with venous thrombosis from the Leiden, Ams-
terdam, and Rotterdam area. Mean age of control sub-
jects was 45 years (range 15–72 years), and 57% was
female.
Demographic and clinical data of NECOSAD patients
The following data were collected between 4 weeks
prior and 2 weeks after the start of chronic dialysis treat-
ment: age, gender, ethnic background, primary kidney
disease, systolic and diastolic blood pressure, comorbid-
ity, body mass index (BMI), and modality. A blood sample
and 24-hour urine sample were obtained simultaneously.
Serum albumin, plasma creatinine, and plasma urea lev-
els were determined. Urea and creatinine were also an-
alyzed in the urine sample. Renal function at 3 months
after start of chronic dialysis treatment was expressed as
glomerular filtration rate (GFR), calculated as the mean
of creatinine and urea clearances, adjusted for body sur-
face area (mL/min/1.73m2).
Primary kidney disease and causes of death were clas-
sified according to the codes of the European Renal
Association-European Dialysis and Transplantation As-
sociation [1]. The following codes were designated as
cardiovascular mortality: 0 (cause of death uncertain/not
determined), 11 (myocardial ischemia and infarction), 12
(hyperkalemia), 14 (other causes of cardiac failure), 15
(cardiac arrest, cause unknown), 16 (hypertensive car-
diac failure), 17 (hypokalemia), 18 (fluid overload), 22
(cerebrovascular accident), 26 (hemorrhage from rup-
tured vascular aneurysm), and 29 (mesenteric infarction).
Comorbidity was defined according to the risk criteria
of Khan et al [26]. The Khan index is a combination of
age and comorbidity leading to three risk groups: low,
medium, and high.
DNA isolation and ACE I/D polymorphism genotyping
Genomic DNA was isolated from peripheral blood
with the Puregene DNA isolation kit (Gentra,
Minneapolis, MN, USA). To identify carriers of the I/D
polymorphism in intron 16 of the ACE gene, a two-step
polymerase chain reaction (PCR) was performed with the
following primers [27]: GIIS: 5′-CTC AAG CAC GCC
CCT CAC AGG ACT G-3′, GAS: 5′- GAT GTG GCC
ATC ACA TTC GTC AGA T-3′ and FYM: 5′-ATC ACG
AGG TCA GGA GAT CGA GAC-3′. Primers GIIS and
GAS were used in the first PCR step, yielding a PCR
product of 274 bp for DD homozygotes, PCR products
of 274 and 561 bp for ID heterozygotes, and a PCR prod-
uct of 561 bp for II homozygotes. Because the D-allele in
heterozygous samples is preferentially amplified, mistyp-
ing between DD and ID is possible. Therefore, a second
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PCR step (using GIIS and FYM primers) that recognizes
an insertion specific sequence, was performed on each
sample. This reaction yields a PCR product (376 bp) only
in the presence of an I-allele.
The PCR conditions for both PCR steps were simi-
lar. All reactions were performed with 8 pmol of each
primer in a final volume of 25 lL containing 10 mmol/L
Tris-HCl (pH 9.0), 1.5 mmol/L MgCl2, 50 mmol/L KCl,
0.01% (w/v) gelatin, 0.1% Triton X-100, 0.5 units Taq
polymerase (SuperTaq; HT Biotechnology, Ltd., Cam-
bridge, UK), 1 mol/L betaı¨ne, 2% DMSO, 1.25 lL of each
dNTPs (Roche Diagnostics, Basel, Switzerland), and 50
to 100 ng genomic DNA. Amplification was performed
for 35 cycles of 35 sec at 94◦C, 40 sec at 62◦C, and 45 sec
at 72◦C, with an initial denaturation period of 3 minutes.
After the last cycle a final extension period of 7 minutes
at 72◦C was used.
Statistical analysis
Hardy-Weinberg equilibrium was calculated using the
gene-counting method and differences were assessed by
chi-square test. Chi-square test was applied to compare
genotype and allele frequencies between NECOSAD pa-
tients and the comparison group.
In patients, differences between ACE groups were
tested with the chi-square test for dichotomous and cat-
egorical variables, and analysis of variance for contin-
uous variables. The survival curve of each ACE group
was determined with the Kaplan-Meier method. The log
rank test was used to determine differences between sur-
vival curves. Hazard ratios (HRs) were calculated by
Cox proportional-hazard regression analysis from the
3-month visit onward. Patients with the II genotype were
used as reference group. HRs were adjusted for age at
the start of dialysis, comorbidity, and ethnic background.
To evaluate whether the association between ACE
genotype and mortality might be the same or different
according to dialysis modality, Cox regression analysis
was performed using a model with 5 dummy variables
as covariates: PD ID, PD DD, HD II, HD ID, and HD
DD. The sixth dummy variable, PD II, was not included
in the Cox regression model because this group was used
as reference group. HRs were adjusted for age at the start
of dialysis, comorbidity, ethnic background, and residual
GFR (measured at 3 months after the start of dialysis). A
difference in effect was evaluated by calculating whether
the differences in HR departed from additivity [28].
All statistical analyses were performed with SPSS sta-
tistical software (version 11; SPSS, Chicago, IL, USA).
RESULTS
Between January 1999 and January 2002, 532 patients
were included in NECOSAD centers that gave permis-
Table 1. ACE genotype and allele distribution
NECOSAD
All patients Caucasians only Comparison group
(N = 453) (N = 415) (N = 472)
ACE N % N % N %
II 110 24.3 96 23.1 112 23.7
ID 227 50.1 208 50.1 235 49.8
DD 116 25.6 111 26.7 125 26.5
P = 0.95a P = 0.98b
I-allele 447 49.3 400 48.2 459 48.6
D-allele 459 50.7 430 51.8 485 51.4
P = 0.76a P = 0.86b
aAll NECOSAD patients versus the comparison group as determined with the
chi-square test.
bCaucasian NECOSAD patients versus the comparison group as determined
with the chi-square test.
sion for DNA analyses. Seventy-nine out of 532 patients
(15%) were not genotyped due to various reasons. In 9
out of these 79 patients either the DNA isolation or the
ACE genotyping failed. Because full blood sampling for
DNA analysis in NECOSAD started in March 2000, we
missed 70 patients that had left the study before blood
could be drawn: 28 patients had died, 20 left the study for
a kidney transplantation, 14 refused further participation
in the study, in 1 patient kidney function recovered, and
7 patients were missed for other reasons. The 79 patients
who were not genotyped showed similar baseline charac-
teristics as the 453 genotyped patients but had a signifi-
cantly lower BMI (23.8 ± 4.6 vs. 25.5 ± 4.8 kg/m2, P =
0.004; data not shown). Further statistical analyses were
performed on the 453 genotyped patients.
Table 1 shows the ACE genotype and allele frequencies
of all NECOSAD patients, Caucasian patients only, and
the comparison group of healthy volunteers. I/D poly-
morphism distribution was within Hardy-Weinberg
equilibrium in all groups. The ACE genotype and allele
distribution of all NECOSAD patients and of Caucasian
patients only was not different from the comparison
group.
As shown in Table 2, patient characteristics of the 3
ACE groups were highly similar at the start of dialysis,
except for a slightly higher number of Caucasians in the
DD group.
The mean follow-up duration of the 453 patients was
2.3 ± 1.2 years, with a maximum of 4.6 years. A total of
154 of the 453 patients died during follow-up. A total of 90
patients received a renal transplant and were censored at
the time of transplantation. Three patients left the study
because of recovery of kidney function and were censored
at that date. Twenty-five patients refused further partici-
pation, 2 patients were transferred to a nonparticipating
dialysis center, and 8 patients left the study for other rea-
sons. The survival times of those 35 patients were cen-
sored at the date of leaving the study. The survival times
of the 171 patients who had not left the study at the end
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Table 2. Baseline demographics of dialysis patients grouped
according to ACE genotype
ACE genotype
II ID DD
(N = 110) (N = 227) (N = 116)
Age years 59 ± 14 59 ± 15 59 ± 14
Gender% male 64 58 63
Modality% HD 66 67 72
Ethnic backgrounda%
Caucasian
87 92 96
Primary kidney disease%
Diabetes mellitus 15 21 10
Glomerulonephritis 16 10 12
Renal vascular disease 17 17 16
Other 52 52 61
Comorbidityb%
Low 40 34 43
Medium 36 36 34
High 24 30 23
Systolic blood pressure
mm Hg
147 ± 26 151 ± 25 148 ± 23
Diastolic blood pressure
mm Hg
82 ± 12 83 ± 13 84 ± 13
Antihypertensive
medicationc% yes
84 88 86
Albumin g/L 35.3 ± 6.8 35.0 ± 6.1 35.7 ± 5.7
BMI kg/m2 25.2 ± 4.5 25.8 ± 4.9 25.3 ± 4.8
Creatinine lmol/L 769 ± 300 743 ± 292 732 ± 253
Urea mmol/L 34.8 ± 12.8 32.1 ± 10.7 35.0 ± 11.3
rGFR mL/min/1.73m2 3.5 ± 2.4 3.9 ± 2.7 4.6 ± 4.9
Renal Kt/Vurea per week 3.0 ± 1.3 2.9 ± 0.9 3.1 ± 1.0
BMI, body mass index; rGFR, residual glomerular filtration rate. All variables
are measured at the start of dialysis, except rGFR and renal Kt/Vurea, which
have been measured 3 months after the start of dialysis. Mean values ± SD are
given for continuous variables.
aP = 0.01, determined with the chi-square test.
bKhan index.
cIncludes the use of b-blockers, a1-blockers, nonselective b- and a-blockers,
central a2-agonists, diuretics, calcium channel blockers, ACE inhibitors,
angiotensin II receptor antagonists, and vasodilators.
of the follow-up period were censored at November 1,
2003. The 2-year survival was 76%. Fifty-nine out of 154
deaths (38%) were cardiovascular. Other causes of death
were infections (N = 16), liver diseases (N = 3), social
(N = 27), miscellaneous (N = 25), accident (N = 1), and
other identified causes of death (N = 3). In 20 of the 154
deceased patients the cause of death was unknown.
Kaplan-Meier curves for all-cause mortality for each
ACE genotype group are shown in Figure 1. There was
a significant difference in crude survival between ACE
genotypes (P = 0.04, log rank test). The 1-year mortality
of II homozygotes, ID heterozygotes, and DD homozy-
gotes was 7%, 11%, and 10%, respectively. The 2-year
mortality was as follows: II subjects 16%, ID subjects
24%, and DD subjects 32%.
HRs for all-cause and cardiovascular mortality were
calculated with Cox regression analyses. Table 3 shows
the crude and adjusted HRs of each ACE genotype group.
After adjustment for age, comorbidity, and ethnic back-
ground, the HRs for all-cause mortality for ID and DD
were 1.55 (95% CI 1.00–2.42) and 2.30 (95% CI 1.41–
Table 3. Association between ACE genotype and all-cause and
cardiovascular mortality
Crude Adjusteda
ACE N HR 95% CI HR 95% CI
All-cause mortality
IIb 110 1.00 1.00
ID 227 1.51 0.99–2.33 1.55 1.00–2.42
DD 116 1.81 1.13–2.91 2.30 1.41–3.75
Cardiovascular mortality
IIb 110 1.00 1.00
ID 227 1.30 0.67–2.54 1.33 0.67–2.67
DD 116 1.59 0.76–3.33 2.06 0.96–4.43
HR, hazard ratio; 95%CI, 95% confidence interval.
aAdjusted for age at the start of dialysis, comorbidity (Khan index), and
ethnic background.
bReference group.
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Fig. 1. Kaplan-Meier survival curve.
3.75), compared to II homozygotes. Regarding cardio-
vascular mortality, patients with the ID and DD geno-
type showed adjusted HRs of 1.33 (95% CI 0.67–2.67)
and 2.06 (95% CI 0.96–4.43). Because the I/D genotype
distribution is known to vary across races [23], we have
also determined HRs for the 415 Caucasians patients sep-
arately. Adjusted HRs of Caucasian patients were similar
to those of the whole study population. Compared to II
subjects, all-cause mortality risks for ID and DD subjects
were 1.49 (95% CI 0.95–2.34) and 2.15 (95% CI 1.31–
3.55). For cardiovascular mortality, ID and DD subjects
had adjusted HRs of 1.32 (95% CI 0.64–2.72) and 1.91
(95% CI 0.86–4.23).
To study whether the association between ACE
genotype and all-cause mortality differed between pa-
tients with various primary kidney diseases, HRs were
calculated for each group of primary kidney disease
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Table 4. Association between ACE genotype and all-cause mortality,
stratified by primary kidney disease
Crude Adjusteda
ACE N HR 95% CI HR 95% CI
Renal vascular disease (N = 76)
IIb 19 1.00 1.00
ID 38 1.46 0.64–3.35 2.04 0.83–4.98
DD 19 1.89 0.76–4.72 3.03 1.12–8.21
Diabetes mellitus (N = 75)
IIb 16 1.00 1.00
ID 47 1.28 0.58–2.87 1.82 0.73–4.53
DD 12 1.83 0.63–5.33 1.99 0.58–6.82
Other (N = 302)
IIb 75 1.00 1.00
ID 142 1.67 0.87–3.19 1.44 0.73–2.84
DD 85 2.21 1.12–4.36 2.60 1.30–5.19
HR, hazard ratio; 95%CI, 95% confidence interval.
aAdjusted for age at the start of dialysis, comorbidity (Khan index), and
ethnic background.
bReference group.
Table 5. Effect of ACE genotype and modality on all-cause mortality
Crude Adjusteda
ACE Modality N HR 95% CI HR 95% CI
IIb PDb 37 1.00 1.00
ID PD 74 2.82 0.96–8.24 2.58 0.85–7.84
DD PD 32 2.36 0.67–8.38 3.09 0.86–11.12
II HD 73 3.52 1.22–10.15 2.04 0.68–6.12
ID HD 153 4.49 1.63–12.36 2.09 0.73–5.98
DD HD 84 5.55 1.98–15.54 3.17 1.07–9.33
HR, hazard ratio; 95%CI, 95% confidence interval.
aAdjusted for age at start dialysis, comorbidity (Khan index), ethnic
background, and residual GFR (measured three months after the start of
dialysis).
bPatients with the II genotype on PD are the reference group.
separately (Table 4). All groups of primary kidney dis-
ease showed a 2- to 3-fold increased adjusted HR for DD
subjects compared to II subjects with the same primary
kidney disease.
Three hundred and ten out of 453 patients had HD as
starting modality, whereas 143 patients started with PD.
To study whether the association between ACE genotype
and all-cause mortality was different for HD and PD pa-
tients, Cox regression analysis was performed using PD
patients with the II genotype as reference group (Table 5).
Among PD patients, DD subjects had an adjusted HR of
3.09, which means that the presence of the DD genotype
increased the HR from 1.00 to 3.09. The HR difference,
2.09, is the effect of DD genotype in PD patients. Among
HD patients, the adjusted HR increased from 2.04 in II
subjects to 3.17 in DD subjects, resulting in an HR differ-
ence of 1.13. Thus, the HR difference among HD patients
was smaller than among PD patients, which is predomi-
nantly due to the higher mortality of HD patients with the
II genotype. However, the confidence intervals around
the estimates were large.
DISCUSSION
In this prospective study of patients who were followed
from the start of dialysis onward, we found a significantly
increased all-cause mortality risk for ID and DD carriers.
The DD genotype also tended to be associated with in-
creased cardiovascular mortality. The positive association
between mortality and the DD genotype was observed in
all groups of primary kidney disease.
The limited amount of available data concerning the
relationship between I/D genotype and mortality in dialy-
sis patients have been contradictory. Two follow-up stud-
ies found a positive association between the D-allele and
mortality [20, 22]. Three follow-up studies [16, 18, 21] that
did not find an association were based on follow-up data
of patients who were already on dialysis treatment for a
varying amount of time. In these studies with so-called
prevalent patients, selection bias might have occurred
since a cohort of prevalent dialysis patients is character-
ized by an over-representation of patients who already
survived relatively long on dialysis treatment. These long-
term survivors might not be equally susceptible anymore
to mortality risk factors compared to ESRD patients who
had already died before they could be included in the
study. As a consequence, the effect of the DD genotype
in prevalent cohorts might be underestimated. To circum-
vent selection bias, our study was performed in so-called
incident patients (i.e., ESRD patients who were followed
from the start of dialysis onward).
One follow-up study among incident dialysis patients
found a significant HR of 2.5 for DD subjects compared
to the other ACE genotypes [20]. Although this study
was performed in Japanese dialysis patients with dia-
betic nephropathy, the HR for all-cause mortality was in
accordance with the findings in our overall study popu-
lation and in our patients with diabetes mellitus. In addi-
tion, we observed an increased mortality risk for patients
with renal vascular disease and other causes of primary
renal failure, indicating that the DD genotype is a risk
factor for mortality irrespective of the underlying kidney
disease.
We were interested in the effect of ACE genotype on
mortality in patients who had reached a stage of kidney
disease requiring dialysis treatment. For this reason we
have studied ACE-related mortality in ESRD patients
who were followed from the start of dialysis onward. The
possibility exists that some patients with the DD geno-
type have died from CVD before they could initiate dial-
ysis treatment. In that case, we would expect to find an
under-representation of the DD genotype in our dialysis
population. To explore this possibility, we have compared
the ACE genotype distribution of our dialysis population
with a comparison group of healthy adults. We found no
differences in genotype distribution between our dialysis
patients and the comparison group.
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Because the NECOSAD study has included HD and
PD patients, we wondered whether the association be-
tween ACE genotype and mortality was different for
HD and PD patients. We showed that the HR differ-
ence between II and DD subjects was larger among PD
patients than among HD patients. This slight difference
was predominantly due to a higher mortality of HD pa-
tients with the II genotype. Given the large confidence
intervals around the estimates, these findings are uncer-
tain. Furthermore, although we have adjusted the anal-
yses for known confounders, some residual confounding
might still be present. Thus, our findings should at present
have no consequences for the choice of modality in DD
subjects.
In our study, ACE genotype data were available for
the majority of our included patients (85%). Although
the 79 untested patients had a lower BMI than the 453
genotyped patients, there were no differences in impor-
tant prognostic factors. Therefore, it does not seem very
likely that serious distortion of our results has occurred.
In an observational follow-up study like NECOSAD,
it is necessary to adjust for confounding factors like age
and comorbidity because these confounders may distort
the association between the risk factor of interest and
the outcome. However, controlling for confounders is in
principle unnecessary when studying the relationship be-
tween a genetic risk factor and outcome [29]. This is be-
cause in the population at large the polymorphism is not
linked to age or any other possible confounder. However,
age and age-related comorbidity could be confounders in
our study if some ESRD patients with the DD genotype
have already died before they could start with dialysis. In
that case, dialysis patients with the DD genotype would
be younger than those with the other ACE genotypes.
In our study we did not observe a difference in age and
comorbidity between the genotype groups. Although ad-
justment was probably unnecessary, adjustment for age
and comorbidity further increased the HRs. This effect of
adjustment must be the result of some association with
age and comorbidity within the NECOSAD data that is
not present in the population at large [29].
Population stratification (PS) is another form of con-
founding that may occur in genetic association studies.
This “confounding by ethnicity” is commonly being re-
ferred to as one of the main reasons for the lack of
replication across population-based studies [30]. Bias due
to PS may occur when a distinct population comprises
subgroups with different genetic background. For ACE
I/D polymorphism it is known that there are ethnic dif-
ferences in genotype distribution [23]. Today, there is
growing evidence that the magnitude of bias caused by
PS is small unless extreme differences exist in genotype
frequencies across the ethnicities [30–32]. In our study,
the genotype distribution of the total dialysis population
was in Hardy-Weinberg equilibrium, indicating that the
population’s genotype and allele frequencies have re-
mained unchanged over successive generations. There-
fore, it seems unlikely that PS is a major problem in our
study population. Furthermore, genotype frequencies of
the total dialysis population and Caucasian patients were
similar. Nevertheless, we have adjusted the HRs for eth-
nic background because we observed a slightly increased
number of Caucasians in the DD group. In addition, re-
striction of the survival analyses to Caucasian patients
only showed HRs similar to the ones of the whole study
population.
In our study, cardiovascular HRs were slightly lower
than all-cause HRs. This suggests that the DD genotype
is not specifically related to cardiovascular death. In fact,
at the moment, the mechanisms by which the D-allele
could lead to an increased risk for CVD and cardiovas-
cular mortality are unknown. Recently, several studies
have provided evidence for a role of the I/D genotype
in the progression and pathogenesis of noncardiovascu-
lar diseases, such as prostate cancer [33] and sepsis [34].
Finally, it should be noted that the I/D polymorphism is
located within an intron. Therefore, the effect on mortal-
ity might be caused by another (functional) variant that
is in linkage disequilibrium with the I/D polymorphism,
and located within or near the ACE gene.
CONCLUSION
We have shown that the DD genotype is associated with
an increased mortality risk in ESRD patients new on dial-
ysis. This positive association was observed in all groups
of primary kidney disease. Further research is necessary
to determine the mechanisms by which the DD genotype
leads to increased mortality.
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